{"id":3860,"date":"2017-02-28T16:23:22","date_gmt":"2017-02-28T16:23:22","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3860"},"modified":"2017-02-28T14:58:07","modified_gmt":"2017-02-28T14:58:07","slug":"precision-studie-kein-freispruch-fuer-celecoxib","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/","title":{"rendered":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib"},"content":{"rendered":"

AMB 2017, 51, 15 PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib Fazit: In der PRECISION-Studie wurden insgesamt >\u00a024.000\u00a0Patienten mit arthritischen Beschwerden und erh\u00f6hten kardiovaskul\u00e4ren Risiken dauerhaft \u2013 durchschnittlich 20\u00a0Monate\u00a0(!) \u2013 in drei Studienarmen mit dem COX-2-Hemmer Celecoxib oder Naproxen oder Ibuprofen behandelt. Die H\u00e4ufigkeit kardiovaskul\u00e4rer Komplikationen war etwa gleich und betrug ca. 1-2%\/Jahr. Celecoxib war also […]<\/p>\n","protected":false},"excerpt":{"rendered":"

AMB 2017, 51, 15 PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib Fazit: In der PRECISION-Studie wurden insgesamt >\u00a024.000\u00a0Patienten mit arthritischen Beschwerden und erh\u00f6hten kardiovaskul\u00e4ren Risiken dauerhaft \u2013 durchschnittlich 20\u00a0Monate\u00a0(!) \u2013 in drei Studienarmen mit dem COX-2-Hemmer Celecoxib oder Naproxen oder Ibuprofen behandelt. Die H\u00e4ufigkeit kardiovaskul\u00e4rer Komplikationen war etwa gleich und betrug ca. 1-2%\/Jahr. Celecoxib war also […]<\/p>\n","protected":false},"author":4,"featured_media":3874,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[438,48,49,51,52,53,54,2603],"class_list":["post-3860","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-allgemein","tag-celecoxib","tag-cox-2-hemmer","tag-coxibe","tag-ibuprofen","tag-naproxen","tag-nichtsteroidale-antiphlogistika","tag-nsaid","tag-precision-studie"],"yoast_head":"\nPRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib<\/title>\n<meta name=\"description\" content=\"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib\" \/>\n<meta property=\"og:description\" content=\"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-28T16:23:22+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2016\/11\/dT1hSFIwY0Rvdkx6Tm.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib\",\"datePublished\":\"2017-02-28T16:23:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/\"},\"wordCount\":348,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2017\\\/02\\\/billionphotos-1439708.jpg\",\"keywords\":[\"Celecoxib\",\"COX-2-Hemmer\",\"Coxibe\",\"Ibuprofen\",\"Naproxen\",\"Nichtsteroidale Antiphlogistika\",\"NSAID\",\"PRECISION-Studie\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/\",\"name\":\"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2017\\\/02\\\/billionphotos-1439708.jpg\",\"datePublished\":\"2017-02-28T16:23:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2017\\\/02\\\/billionphotos-1439708.jpg\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2017\\\/02\\\/billionphotos-1439708.jpg\",\"width\":500,\"height\":333},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/precision-studie-kein-freispruch-fuer-celecoxib\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib","description":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/","og_locale":"de_DE","og_type":"article","og_title":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib","og_description":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2017-02-28T16:23:22+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2016\/11\/dT1hSFIwY0Rvdkx6Tm.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib","datePublished":"2017-02-28T16:23:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/"},"wordCount":348,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2017\/02\/billionphotos-1439708.jpg","keywords":["Celecoxib","COX-2-Hemmer","Coxibe","Ibuprofen","Naproxen","Nichtsteroidale Antiphlogistika","NSAID","PRECISION-Studie"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/","name":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2017\/02\/billionphotos-1439708.jpg","datePublished":"2017-02-28T16:23:22+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2017\/02\/billionphotos-1439708.jpg","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2017\/02\/billionphotos-1439708.jpg","width":500,"height":333},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/precision-studie-kein-freispruch-fuer-celecoxib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"PRECISION-Studie \u2013 kein Freispruch f\u00fcr Celecoxib"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3860"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3860\/revisions"}],"predecessor-version":[{"id":3861,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3860\/revisions\/3861"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media\/3874"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}